NHS
East Genomic Laboratory Hub

NHS East Genomic Laboratory Hub
Cambridge Genomics Laboratory
Cambridge University Hospitals Foundation Trust
Cambridge, CB2 0QQ

15th November 2022

RE: Change in East GLH Inherited Cancer Laboratory Service Delivery

Dear Colleagues

I would like to inform you of a change in service delivery for Inherited Cancer genomic tests in the East GLH region. The associated Rare Disease Test Directory Clinical Indications are listed in the table below.

From the 1st of January 2023, all test orders and samples received for these Clinical Indications will be processed in the Cambridge Laboratory. Analysis and reporting will be performed by both the Cambridge and Nottingham Clinical Scientist Teams using standardised processes and reporting templates.

This change in service will provide the additional gene content specified for the core Inherited Cancer Clinical Indications in the Rare Disease Test Directory and provides copy number screening for all genes tested.

You do not need to change your current practice or sample routing. Continue to send test orders and samples to your local genomics laboratory in Cambridge, Leicester or Nottingham. It is important that you indicate patient eligibility for the Clinical Indication requested on the test order form as testing will only be activated if eligibility criteria for the patient are met.

We aim to meet the prescribed national turnaround times for these tests (in table below). If the results of testing will affect imminent treatment decisions and/or surgical management of a patient we will prioritise testing. For these patients mark as urgent on the test order form and state the reason for urgency to enable the team to prioritise testing appropriately.

Please contact me or your local laboratory teams if you have any queries

Yours sincerely

Kate Downes
PhD, Clinical Scientist
East GLH - Lead Scientist for Rare and Inherited Disease
email: katedownes@nhs.net

Code	Clinical Indication	Genes	Turn Around Time
R207	Inherited ovarian cancer (without breast cancer)	BRCA1, BRCA2, BRIP1, MLH1, MSH2, MSH6, PALB2, RAD51C, RAD51D	42 days
R208	Inherited breast cancer and ovarian cancer	ATM, BRCA1, BRCA2, CHEK2, PALB2, RAD51C, RAD51D	42 days
R210	Inherited MMR deficiency (Lynch syndrome)	EPCAM, MLH1, MSH2, MSH6, PMS2	42 days
R211	Inherited polyposis and early onset colorectal cancer - germline testing	APC, BMPR1A, EPCAM, GREM1, MLH1, MSH2, MSH6, MUTYH, NTHL1, PMS2, POLD1, POLE, PTEN, RNF43, SMAD4, STK11	84 days
R414	APC associated Polyposis	APC	42 days